Industry News
Biotechnology Industry News
The 552 million pounds ($747…
The 552 million pounds ($747 million) raised by British biotechs in the first quarter of the year has been hailed as a “sign of recovery,” although an anticipated resurgence of IPOs across the nation has
The FDA is awarding national…
The FDA is awarding national priority vouchers to Compass Pathways, Usona Institute and Transcend Therapeutics for their psychedelic treatments. A third recipient in this batch is Transcend Therapeutics, which is being acquired by Otsuka, according
Avalyn Pharma is hoping to rake in…
Avalyn Pharma is hoping to rake in around $181.8 million from an IPO, which the biotech will use to take its inhaled versions of approved drugs for respiratory conditions into late-stage studies.
Two months after bringing in…
Two months after bringing in Michael Cola to man the helm at Helus Pharma, the company’s board has requested his departure, effective immediately. As such, co-founder and executive chairman Eric So will again take on
Despite the recent “feeding…
Despite the recent “feeding frenzy,” Pitchbook’s Ben Zercher told Fierce he expects in vivo CAR-T dealmaking to slow due to a shortage of viable acquisition targets.
Pfizer has abandoned work on a…
Pfizer has abandoned work on a PD-L1-targeting drug that was being tested in patients with various cancers.
While Big Pharmas embarked on a…
While Big Pharmas embarked on a frenzy of acquisitions over recent weeks, Roche’s CEO has explained to Fierce why the Swiss drugmaker is happy to sit this round out.
As Sanofi counts down the days…
As Sanofi counts down the days before its new leader arrives, the pharma's CFO acknowledged to Fierce that there have been a “certain number of setbacks.”
Just a few months after ripping up…
Just a few months after ripping up the central nervous system-focused portion of its RIPK1 deal with Rigel Pharmaceuticals, Eli Lilly has now thrown out the rest of the pact, too.
Kurma Partners has closed its…
Kurma Partners has closed its fourth biotech venture capital fund after raising 215 million euros ($252 million) to support European startups.
A little over a year after…
A little over a year after reabsorbing its anticoagulant abelacimab, Novartis has now terminated two phase 3 trials for the antibody.
Kyverna Therapeutics has unveiled…
Kyverna Therapeutics has unveiled the full results from its registrational trial of miv-cel in stiff person syndrome (SPS), providing a comprehensive look at what could become the first-ever CAR-T therapy approved for an autoimmune disease.
Roche has shared details of…
Roche has shared details of fatalities in its phase 3 relapsing multiple sclerosis trials, revealing that deaths from infections, diabetes complications and an accident contributed to an imbalance between the fenebrutinib and control cohorts.
A pair of Sage veterans has…
A pair of Sage veterans has launched a neurology-focused startup armed with $106 million and a clinical-stage pipeline of assets licensed from Eisai and Hansoh.
Gene therapy biotech Ray…
Gene therapy biotech Ray Therapeutics has announced the closing of a $125 million series B financing to support the company’s vision restoration candidates for patients with retinal degeneration.
Gilead and Arcus’ domvanalimab,…
Gilead and Arcus' domvanalimab, one of the last anti-TIGIT antibodies still standing, has failed another trial—leading Gilead to pull further away from their once wide-ranging collaboration.
Replimune is saying goodbye to a…
Replimune is saying goodbye to a further 161 staffers across two Massachusetts sites.
Since its 2014 founding, Zai Lab…
Since its 2014 founding, Zai Lab has built its business by licensing drugs from Big Pharma. But in the last three years, the company has sought to leverage its footholds in China and the U.S.
Eli Lilly is picking up its second…
Eli Lilly is picking up its second in vivo CAR-T company of the year, paying $3.25 billion in upfront cash for Kelonia Therapeutics and its phase 1-stage myeloma therapy.
Following its move to secure…
Following its move to secure ex-China rights to the CD38-directed antibody felzartamab, Biogen is doubling down and building on an existing partnership with local drugmaker TJ Biopharma.